|
시장보고서
상품코드
1422743
세계의 성장 호르몬 결핍증 시장 예측(-2027년)Growth Hormone Deficiency Market Research Report Forecast to 2027 |
||||||
성장 호르몬 결핍증 시장 규모는 예측 기간 동안 4.19%의 연평균 복합 성장률(CAGR)로 견조한 성장세를 보일 것으로 예상됩니다.
성장 호르몬 결핍증 시장은 분석의 발전, 마음 챙김의 확대, 치료 옵션의 확장으로 인해 크게 성장하고 있습니다. 성장 호르몬 결핍이 건강에 미치는 영향에 대한 인식이 높아지고, R&D 노력의 진전이 더해지면서 시장이 확대될 것으로 예상됩니다.
지역별로는 미주 지역이 2022년 가장 큰 점유율을 차지했습니다. 의료 서비스 프레임워크 구축, 기계적 진보의 확대, 많은 사업자의 존재 등의 요인이 이 점유율에 기여하고 있습니다. 반면, 아시아태평양은 예측 기간 동안 가장 큰 성장을 보일 것으로 예상됩니다. 이러한 성장은 치료의 발전, R&D의 자산 확대, 성장 호르몬 결핍증의 발병률 증가에 기인합니다.
세계 성장 호르몬 결핍증(Growth Hormone Deficiency) 시장을 조사했으며, 시장 정의와 개요, 시장 성장에 영향을 미치는 각종 영향요인 분석, 시장 규모 추이 및 예측, 각종 부문별/지역별 분석, 경쟁 환경, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.
목차
제1장 주요 요약
제2장 시장 개요
제3장 조사 방법
제4장 시장 역학
- 성장 촉진요인
- 성장 억제요인
- 기회
- 임상시험 분석
- 메가트렌드
- 거시경제 지표
- 법규제 및 새로운 치료 스킴
- LAGH(LONG ACTING GROWTH HORMONES)
제5장 시장 영향요인 분석
- 공급망 분석
- Porter의 Five Forces 분석
- COVID-19의 영향
- 성장 호르몬 결핍증 유형 : 역학 데이터
제6장 세계의 성장 호르몬 결핍증 시장 : 브랜드별
- 개요
- NORDITROPIN
- GENOTROPIN
- HUMATROPE
- SAIZEN
- OMNITROPE
제7장 세계의 성장 호르몬 결핍증 시장 : 용도별
- 개요
- 소아 성장 호르몬 결핍증
- 특발성 저신장
- SGA
- 터너 증후군
- 성인 성장 호르몬 결핍증
- 프래더 윌리 증후군
제8장 세계의 성장 호르몬 결핍증 시장 : 투여 경로별
- 개요
- 피하
- 근육내
- 정맥내
제9장 세계의 성장 호르몬 결핍증 시장 : 유통 채널별
- 개요
- 병원 약국
- 소매 약국
- 클리닉
- E-Commerce 웹사이트
제10장 세계의 성장 호르몬 결핍증 시장 : 지역별
- 개요
- 북미
- 유럽
- 아시아태평양
- 중동 및 아프리카
- 라틴아메리카
제11장 경쟁 구도
- 개요
- 세계 시장 점유율 분석
- 경쟁 벤치마킹
- 주요 성장 전략
- 개발 건수 주요 기업
- 주요 발전과 성장 전략
제12장 기업 개요
- MERCK KGAA
- NOVO NORDISK A/S
- ELI LILY AND COMPANY
- F. HOFFMAN LA ROCHE LTD
- PFIZER, INC.
- NOVARTIS AG
- IPSEN PHARMA
- FERRING PHARMACEUTICALS
- ANKEBIO CO., LTD
- ZHONGSHAN SINOBIOWAY HYGENE BIOMEDICINE CO., LTD
제13장 부록
LSH 24.02.21Market Overview
The Growth Hormone Deficiency Market is anticipated to register a healthy CAGR of 4.19% during the review period.
The growth hormone deficiency market is encountering critical growth driven by headways in analysis, expanding mindfulness, and extending treatment choices. Developing acknowledgment of the effect of growth hormone deficiency on wellbeing, combined with progressing research and improvement endeavors, positions this market for proceeded with extension soon.
The growth of the Growth Hormone Deficiency Market is supposed to be driven by the rising number of people experiencing growth hormone deficiency (GHD), rising mindfulness in regard to the adequacy of GH alongside clinical preliminaries zeroed in on the security and viability of GHD, and the changing way of life alongside the developing predominance of hereditary problems.
As per the distributed article in NCBI in Walk 2017, the assessed commonness of GHD is roughly 2-3 out of 10,000 populaces. GHD is brought about by primary pituitary sickness or cranial illumination and happens with regards to extra elements of hypopituitarism. Pituitary adenomas are reported to cause grown-up beginning GHD followed by craniopharyngiomas, which represents roughly 57% of cases. What's more, adolescence beginning growth hormone deficiency (CO-GHD) is one of the perplexing endocrine circumstances that might have an effect over the course of life, beginning in youth, and going on till adulthood. Most of the CO-GH is reported to be intrinsic. The fundamental co-morbidities and side effects of GHD in grown-ups and kids are heftiness, diabetes mellitus, hypertension, cerebrovascular illnesses, cardiovascular sicknesses, and liver sicknesses. This rising bleakness of GH sickness in the two kids and grown-ups is supposed to drive the growth of the growth hormone deficiency market.
Market Segmentation
Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, and more brands are included in the Growth Hormone Deficiency Market segmentation based on brand.
The market is divided into categories according to the application: prader-willi syndrome, turner syndrome, adult growth hormone deficit, small for gestational age, idiopathic short stature, and others.
The subcutaneous, intramuscular, and intravenous routes of delivery are used to segment the growth hormone deficiency market. Clinics, e-commerce websites, hospital pharmacies, and retail pharmacies make up the market's distribution channels.
Regional Insights
The Americas growth hormone deficiency market represented the biggest market share in 2022. Key elements ascribed to its huge offer incorporate created medical services framework, expanding mechanical headway, and the presence of many market players in the region.
Europe growth hormone deficiency market represented the second-biggest market share because of developing predominance of GHD people, and the rising attention to treatment.
The Asia-Pacific growth hormone deficiency market is supposed to be the quickest developing from 2023 to 2027 because of developing progression in treatment, expanding assets in research exercises, and rising pervasiveness of GHD.
Major Players
Key Companies in the Growth Hormone Deficiency market includes Novo Nordisk A/S (Denmark), Pfizer, Inc. (US), Merck KGaA (Germany), Eli Lily and Company (Netherlands), Novartis AG (Switzerland), Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Ispen Pharma (Switzerland), Ferring Pharmaceuticals (Switzerland), AnkeBio Co., Ltd (China), and Zhongshan Sinobioway Hygene Biomedicine Co., Ltd (China).
TABLE OF CONTENTS
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
- 2.1 DEFINITION
- 2.2 SCOPE OF THE STUDY
- 2.3 RESEARCH OBJECTIVE
- 2.4 MARKET STRUCTURE
- 2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
- 3.1 DATA MINING
- 3.2 SECONDARY RESEARCH
- 3.3 PRIMARY RESEARCH
- 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
- 3.5 FORECASTING TECHNIQUES
- 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
- 3.7 DATA TRIANGULATION
- 3.8 VALIDATION
4 MARKET DYNAMICS
- 4.1 OVERVIEW
- 4.2 DRIVERS
- 4.2.1 INCREASING INCIDENCE OF GROWTH HORMONE DEFICIENCY
- 4.2.2 RISING NUMBER OF CLINICAL TRIAL FOR GH DEFICIENCY
- 4.2.3 GOVERNMENT INITIATIVES FOR GHD
- 4.2.4 INCREASING NUMBER OF PRODUCT LAUNCH AND STRATEGIC COLLABORATIONS AMONG MARKET PLAYERS
- 4.3 RESTRAINTS
- 4.3.1 HIGH COST OF GHD TREATMENT
- 4.3.2 INCREASING COUNTERFEIT PRODUCTS FOR GHD TREATMENT
- 4.4 OPPORTUNITIES
- 4.4.1 STRONG PIPELINE OF HORMONAL DRUGS AND EASY AVAILABILITY OF PHARMA DRUGS ON E-COMMERCE PLATFORMS
- 4.5 CLINICAL TRIALS ANALYSIS
- 4.6 MEGATRENDS
- 4.6.1 ADVENT OF LONG-ACTING RECOMBINANT HUMAN GROWTH HORMONE (RHGH)
- 4.6.2 USE OF HGH AS PERFORMANCE ENHANCERS AND ANTI-AGING AGENTS
- 4.6.3 PRODUCTS UNDER DEVELOPMENT
- 4.7 MACROECONOMIC INDICATORS
- 4.8 GOVERNMENT REGULATIONS AND NEW TREATMENT SCHEMES
- 4.9 LONG ACTING GROWTH HORMONES (LAGH)
- 4.9.1 OVERVIEW
- 4.9.2 DEVELOPMENT
- 4.9.3 UPCOMING PRODUCTS
- 4.9.4 TRENDS
5 MARKET FACTOR ANALYSIS
- 5.1 SUPPLY CHAIN ANALYSIS
- 5.1.1 RESEARCH AND DEVELOPMENT
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION
- 5.1.4 MARKETING AND SALES
- 5.1.5 POST-SALES MONITORING
- 5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 RIVALRY
- 5.3 IMPACT OF COVID-19
- 5.3.1 OVERVIEW
- 5.3.2 IMPACT ON SUPPLY CHAIN
- 5.3.3 IMPACT ON PRODUCTION
- 5.4 EPIDEMIOLOGY DATA ON TYPE OF GROWTH HORMONE DEFICIENCY DISEASES (2022)
6 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY BRAND
- 6.1 OVERVIEW
- 6.2 NORDITROPIN
- 6.3 GENOTROPIN
- 6.4 HUMATROPE
- 6.5 SAIZEN
- 6.6 OMNITROPE
7 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION
- 7.1 OVERVIEW
- 7.2 PAEDIATRIC GROWTH HORMONE DEFICIENCY
- 7.3 IDIOPATHIC SHORT STATURE
- 7.4 SMALL FOR GESTATIONAL AGE
- 7.5 TURNER SYNDROME
- 7.6 ADULT GROWTH HORMONE DEFICIENCY
- 7.7 PRADER-WILLI SYNDROME
8 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION
- 8.1 OVERVIEW
- 8.2 SUBCUTANEOUS
- 8.3 INTRAMUSCULAR
- 8.4 INTRAVENOUS
9 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL
- 9.1 OVERVIEW
- 9.2 HOSPITAL PHARMACIES
- 9.3 RETAIL PHARMACIES
- 9.4 CLINICS
- 9.5 E-COMMERCE WEBSITES
10 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY REGION
- 10.1 OVERVIEW
- 10.2 AMERICAS
- 10.2.1 NORTH AMERICA
- 10.2.1.1 US
- 10.2.1.2 CANADA
- 10.2.2 LATIN AMERICA
- 10.2.1 NORTH AMERICA
- 10.3 EUROPE
- 10.3.1 WESTERN EUROPE
- 10.3.1.1 GERMANY
- 10.3.1.2 FRANCE
- 10.3.1.3 UK
- 10.3.1.4 ITALY
- 10.3.1.5 SPAIN
- 10.3.1.6 REST OF WESTERN EUROPE
- 10.3.2 EASTERN EUROPE
- 10.3.1 WESTERN EUROPE
- 10.4 ASIA-PACIFIC
- 10.4.1 JAPAN
- 10.4.2 CHINA
- 10.4.3 INDIA
- 10.4.4 AUSTRALIA
- 10.4.5 SOUTH KOREA
- 10.4.6 REST OF ASIA-PACIFIC
- 10.5 MIDDLE EAST AND AFRICA
- 10.5.1 MIDDLE EAST
- 10.5.2 AFRICA
11 COMPETITIVE LANDSCAPE
- 11.1 OVERVIEW
- 11.2 GLOBAL GROWTH HORMONE DEFICIENCY MARKET SHARE ANALYSIS (2019)
- 11.3 COMPETITIVE BENCHMARKING
- 11.4 MAJOR GROWTH STRATEGIES IN THE GLOBAL GROWTH HORMONE DEFICIENCY MARKET
- 11.5 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL GROWTH HORMONE DEFICIENCY MARKET
- 11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.6.1 EXPANSION
- 11.6.2 PRODUCT APPROVAL/FDA APPROVAL
12 COMPANY PROFILES
- 12.1 MERCK KGAA
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 PRODUCTS/SERVICES OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
- 12.2 NOVO NORDISK A/S
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 PRODUCTS/SERVICES OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 SWOT ANALYSIS
- 12.2.6 KEY STRATEGIES
- 12.3 ELI LILY AND COMPANY
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 PRODUCTS/SERVICES OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 SWOT ANALYSIS
- 12.3.6 KEY STRATEGIES
- 12.4 F. HOFFMAN LA ROCHE LTD
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS/SERVICES OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 SWOT ANALYSIS
- 12.4.6 KEY STRATEGIES
- 12.5 PFIZER, INC.
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS/SERVICES OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 SWOT ANALYSIS
- 12.5.6 KEY STRATEGIES
- 12.6 NOVARTIS AG
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS/SERVICES OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 SWOT ANALYSIS
- 12.6.6 KEY STRATEGIES
- 12.7 IPSEN PHARMA
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS/SERVICES OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 SWOT ANALYSIS
- 12.7.6 KEY STRATEGIES
- 12.8 FERRING PHARMACEUTICALS
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS/SERVICES OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 SWOT ANALYSIS
- 12.8.6 KEY STRATEGIES
- 12.9 ANKEBIO CO., LTD
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS/SERVICES OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 SWOT ANALYSIS
- 12.9.6 KEY STRATEGIES
- 12.10 ZHONGSHAN SINOBIOWAY HYGENE BIOMEDICINE CO., LTD
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS/SERVICES OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 SWOT ANALYSIS
- 12.10.6 KEY STRATEGIES
13 APPENDIX
- 13.1 REFERENCES
- 13.2 RELATED REPORTS
